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Abstract
It is well established that Multiple Sclerosis (MS) is an immune mediated disease. Little is known about what drives the
differential control of the immune system in MS patients compared to unaffected individuals. MicroRNAs (miRNAs) are small
non-coding nucleic acids that are involved in the control of gene expression. Their potential role in T cell activation and
neurodegenerative disease has recently been recognised and they are therefore excellent candidates for further studies in
MS. We investigated the transcriptome of currently known miRNAs using miRNA microarray analysis in peripheral blood
samples of 59 treatment naı ¨ve MS patients and 37 controls. Of these 59, 18 had a primary progressive, 17 a secondary
progressive and 24 a relapsing remitting disease course. In all MS subtypes miR-17 and miR-20a were significantly under-
expressed in MS, confirmed by RT-PCR. We demonstrate that these miRNAs modulate T cell activation genes in a knock-in
and knock-down T cell model. The same T cell activation genes are also up-regulated in MS whole blood mRNA, suggesting
these miRNAs or their analogues may provide useful targets for new therapeutic approaches.
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Introduction
Multiple Sclerosis (MS) is a disease which affects mainly young
people that often leaves them disabled in their most productive
years. It is a relatively common disease with an incidence
somewhere between 1–2 per 1000 and the rate appears to be
increasing [1]. It is assumed that a T cell dysregulation results in
demyelination and axonal loss throughout the central nervous
system [2]. Most patients have a relapsing remitting course
(RRMS), which is unpredictable and is observed as episodes of
acute inflammation that results in neurological dysfunction, which
in the majority of cases responds to immunomodulatory steroid
treatment. Relapsing remitting disease is characterized by some
level of myelin repair, whereas in the progressive form myelin
repair seems to be insufficient or ineffectual resulting in progressive
disability without any observable signs of recovery.
In recent years genome wide association studies have identified
that not only is there an association with haplotype in the Human
Leukocyte Antigen (HLA) region, but also in both the IL-2 and the
IL-7 receptor genes, CD56, CD226 and CLEC16A, which together
are considered to contribute to a predisposition to develop the
disease [3–5].
In the largest single genome wide association study searching for
genetic risk factors for MS, polymorphisms associated with the disease
confirmed the importance of immune dysfunction [5]. These identified
polymorphisms alone or in combination do not explain the significant
differences in immune function associated with this disease.
MicroRNAs (miRNAs) have recently been discovered to be
regulatory modulators of gene expression [6]. A striking feature
of these mRNA regulators is their evolutionary conservation,
indicating their level of importance in the control of gene
expression [7]. MiRNAs bind to the 39 UTR of target mRNA
through base pairing, resulting in target mRNA cleavage or
translation inhibition [8]. On average each miRNA regulates
about 200 genes, and the outcome of regulation is cell state and
type specific [9]. Their dysregulation has been associated with
many diseases, and the potential for modulating their action by
therapeutic intervention has excited much interest [10].
This is particularly so in immune-related diseases. The miRNA
transcriptome of immune cell subsets are distinct, suggesting that
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h.naı ¨ve, effector and central memory T cell [11] and regulatory T
cell [12] function is dependent on the miRNA regulation. Gross
changes to mouse miRNA regulation by deletion of the genes
which mediate it, Dicer and Drosher, results in T cell
abnormalities and autoimmune disease [13]. Autoimmune diseases
such as MS are ameliorated by drugs modulating T cell function
like interferon beta and glatiramer acetate, and with monoclonal
antibodies specific to T cell surface markers [14]. The genes which
are associated with this, and other autoimmune diseases, are
predominately expressed in antigen presenting cells and T cells,
and there is a marked T cell activation gene expression pattern in
MS whole blood [15–17]. One of the difficulties of studying
multiple sclerosis is the acquisition of samples unaffected by the
influence of immunomodulatory treatment. In this report we have
investigated miRNA expression profiles of a series of effectively
treatment naı ¨ve MS patients (i.e. all patients were free of disease
modifying therapy for at least 3 months) compared to a healthy
age-matched control group. The findings of this study demonstrate
the differences between the immune function in MS without the
influence of any treatment regiment.
Results
We measured the known miRNA transcriptome in whole blood
from 59 MS patients and 37 healthy controls using the Illumina
sentrix array matrix. Of these 59 patients, 18 had a primary
progressive (PPMS), 17 a secondary progressive (SPMS) and 24 a
relapsing remitting course. The patient demographics are shown
in table S1. To ensure we were not measuring effects due to
diurnal variation in immune function, all samples were collected
between the hours of 9am–1pm for both the MS and healthy
control populations. All of our patients were of Caucasian origin,
and had not received any immunomodulatory therapy within the
previous 3 months. The female to male ratio was 2:1 similar to the
disease incidence in the general MS population. The age range for
the entire group was 32 to 81 years with a mean age of 54 years,
mean time since diagnosis was 20 years, ranging from 0 to 58
years, mean expanded disability status scale (EDSS) was 4.5
ranging from 0 to 6. There was no significant difference in the
demographics between the group assessed by microarray and the
one assessed by RT-PCR. As expected the disease duration and
the EDSS was higher in the SP and PP group compared to the RR
group.
MiRNA expression analysis revealed that out of 733 miRNAs
assessed, 26 were down-regulated and 1 up-regulated in MS whole
blood, based on a false discovery rate of less than 1% (Table 1).
The fold change ranged between 1.36 and 21.59. The down-
regulation of miRNAs was across all the subtypes of MS. Out of
the 27 we focused on miR-17 and miR-20a as the differential
expression analysis revealed that these miRNAs were the most
significantly different in the MS group compared to the controls.
Both miRNAs are known to be involved in immune function and
their importance was confirmed by RT-PCR performed between
3 and 6 times. Both miRNAs were differently expressed across all
MS subtypes (Figure 1). Most significantly different was miR-17
with a p-value of 7.61 e-05 (see Table 2).
To better define the effects of miR-17 and miR-20a on gene
expression we conducted knock-in (with synthetic miRNA) and
knock-down (with LNA modified anitmiRs) experiments using
Jurkat cells (performed in triplicate). Genes down-regulated by the
miR-17 transformants, and up-regulated by the transformants of
small interfering RNAs (siRNAs) corresponding to it were
identified using Illumina HT12 microarrays and differential
expression analysis (table S2). Similarly, genes potentially regulat-
ed by miR-20a were identified (table S3). Putative targets for
miRNAs can be identified from their sequences, and we identified
these using target prediction metadata collated in the miRecords
database (http://mirecords.umn.edu/miRecords).
Genes that were differentially expressed as a result of knock-in
or knock-down were compared against the predicted targets of the
respective miRNA using in silico analysis. The resulting lists of
genes were considered more likely to be directly affected by the
changes in miRNA.
Gene expression data was used to identify gene pathways over-
represented in the set of dysregulated genes in the transformed
Jurkat cells using GeneGo maps module of Metacore (Genego,
MI) (tables S4, S5). Translation (P,10
24 for miR-20a), cholesterol
biosynthesis (P,10
25 for miR-20a, 10
24 for miR-17) and immune
response pathways (P,10
24 for miR-17) were over-represented in
the list of genes dysregulated by changes in miRNA expression.
We then tested if the genes regulated by the miRNAs miR-17
and 20a in Jurkat cells were also over-represented in MS whole
blood. We previously reported, from a comparison of whole blood
transcriptomes of 150 MS patients and controls, that T cell
activation genes were markedly up-regulated in MS (P,10
214)
[15]. We compared the gene expression profiles from transformed
Jurkat cells against non-transformed cells. Putative miR-17 or
miR-20a target genes were then compared with gene expression
Table 1. miRNAs dysregulated in MS whole blood.
Gene Name Fold-Change D Value
hsa-miR-768-3p:11.0 1.36 3.81
HS_265.1 21.13 23.06
hsa-let-7d 21.14 22.85
hsa-let-7f 21.34 23.81
hsa-let-7g 21.19 23.66
hsa-let-7i 21.11 23.27
hsa-miR-106a:9.1 21.3 24.09
hsa-miR-126 21.22 23.68
hsa-miR-126* 21.51 23.66
hsa-miR-140-5p 21.32 22.87
hsa-miR-15a 21.12 22.89
hsa-miR-15b 21.07 23.14
hsa-miR-16 21.08 23.18
hsa-miR-17 21.59 24.72
hsa-miR-20a 21.18 24.44
hsa-miR-20b 21.25 23.31
hsa-miR-211 21.09 22.92
hsa-miR-27a 21.32 23.27
hsa-miR-27b 21.26 23.47
hsa-miR-374a 21.26 24.27
hsa-miR-454 21.54 23.94
hsa-miR-510 21.13 22.98
hsa-miR-579 21.18 22.77
hsa-miR-623 21.17 22.95
hsa-miR-624* 21.25 22.83
hsa-miR-93 21.08 23.72
hsa-miR-98 21.49 24.18
doi:10.1371/journal.pone.0012132.t001
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to be affected by these miRNAs.
From just the mRNA and transformed Jurkat cell list, the
pathways represented were very similar to the pathways over-
represented in mRNA alone (Figure 2). Genes which were on all
three lists were the most likely to be regulated by the miRNA in
MS. From all 3 lists, transcription (P,10
26) and immune response
pathways (P,10
25) were over-represented for miR-20a; and the
Th17 immune response pathway (P,10
23) for miR-17.
Discussion
Dysregulation of the immune system in MS is considered to be a
fundamental aspect of disease initiation and development in this
neurodegenerative disease. In this report we have investigated the
miRNA transcriptome in a series of MS patients who were not on
current immunomodulatory treatment. 59 clinically definite MS
patients (mean age of 54.2 years), enriched for PP subtype (n=18),
with 24 RR and 17 SP were included in the analysis compared to
37 controls (mean age 48.0 years). The mean disease duration
even for the relapsing remitting group was over 15 years. The
selection of treatment naı ¨ve patients suggests that they were not a
group with high disease activity. It could be argued that the
significance of the findings of miR-17 and miR-20a being down
regulated is underestimated compared to a more active northern
European MS population. From the miRNA transcriptome
comprising 733 miRNA species only one was up-regulated
whereas 26 miRNAs were down-regulated with a false discovery
rate less than one. From this data we focused on two miRNAs,
miR-17 and miR-20a, as these were all under-expressed in all
subtypes of MS and are known to be involved in the control of
immune function [18].
Although miR-17 and miR-20a are encoded in the same cistron
(miR-17-92), other miRNAs from this cistron were not under-
expressed, and these two miRNAs were not identically expressed.
There appears to be post-transcriptional regulation of the cistron
miRNAs, allowing them to regulate different processes [19]. The
translation pathway of lymphocytes is orchestrated by miR-17 and
miR-20a [20]. Elevated expression of miR-17 and related
miRNAs has been found to be associated with lymphoma and
other cancers, and is probably important in maintaining an
undifferentiated phenotype and resisting apoptosis [21,22]. A
reduction of miR-17-92 miRNAs observed in the present study,
has also been associated with differentiation [23] and could
potentially be involved in MS-associated T cell activation. We
have previously demonstrated that mRNAs from these pathways
were up-regulated in all clinical subtypes of MS [15]. In order to
test whether these down-regulated miRNAs, miR-17 and 20a
inhibit the expression of these T cell mRNAs we used knock in
(with the miRNAs) and knock-down (with the antisense or siRNAs)
assays of Jurkat cells, a model for T cells.
Jurkat cells are derived from a T cell lymphoma patient, and
have traits of a partially differentiated T cell line [24,25]. The
transformed Jurkat cells were not stimulated, whereas the T cells in
whole blood represent a myriad of subsets in various states of
stimulation. However, as these miRNAs under-expressed in MS
were known to increase transcription of genes involved with
translation and immune response pathways, we expected they may
also contribute to the pattern of gene dysregulation seen in MS
whole blood mRNA. The set of genes down-regulated by miR-17
and miR-20a in transformed Jurkat cells overlap with the genes
and the pathways they are predicted to control, suggesting these
miRNAs contribute to the gene dysregulation observed in whole
blood.
Figure 1. Relative expression of target miRNA. Relative expression of target miRNA compared to endogenous control miRNA in MS subtypes
and healthy controls, validation by Q-RTPCR. The two miRNAs were significantly under-expressed in MS patients compared to healthy controls
(*P,0.05, **P,0.01), error bars 6 SEM.
doi:10.1371/journal.pone.0012132.g001
Table 2. P values of relative expression of target miRNAs.
miR-17 miR-20a
MS(total) 7.61E-05 9.43E-04
RR 4.21E-03 1.95E-02
SP 1.39E-02 5.00E-02
PP 3.20E-02 4.68E-02
P-values of the relative expression as determined by Q-RTPCR of miR-17 and
miR-20a in MS patients as a whole and their respective subgroups compared
against a healthy aged-matched population.
doi:10.1371/journal.pone.0012132.t002
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investigating the role of miRNA in MS [26–30], four of which
focus on the immune system in MS and the other on active and
inactive central nervous system lesions. Otagui et al. [29] focused
more on up-regulation during relapse. As they only examined
small number of patients, their qPCR did not reach statistical
significance. Keller et al. [28] examined 20 RRMS patients on
treatment and identified a number of miRNAs that were up or
down regulated. The report by Du et al. [26] identified miR-326 as
a major determinant of disease in Chinese MS but not
neuromyelitis optica (an inflammatory demyelinating disorder
thought to be mediated by antibodies targeting aquaporin 4 [31]).
In our study we did not identify any statistically significant change
in miR-326 between MS patients and controls. Furthermore,
subgroup analysis confirmed this finding. Since we do not know
why this miRNA was chosen for analysis by Du et al. [26] we are
unable to put forward any functional explanation to describe our
discrepant results apart from differences observed in MS patients
from Asian or Caucasian origin.
The results of this investigation indicate that miR-17 and miR-
20a are implicated in the development of MS. Of special interest is
miR-17 which we found to be down regulated in peripheral blood.
Interestingly, Lindberg et al. [30] also identified miR-17 as being
associated with MS in CD4
+ cells, but the relationship was in the
opposite direction to what we observed. This is likely to be a result
of a type 1 error given that only 8 patients and 10 controls were
examined by Lindberg et al. in their initial miRNA expression
analysis and only 15 patients and 10 controls in their confirmatory
study. This in combination with our study design that included the
three major subgroups of MS whereas the patients participating in
the Lindberg report were diagnosed with relapsing remitting
disease only could potentially explain the differences observed in
miR-17 expression. In our analysis we have examined 59 cases
against 37 controls thereby providing a more robust statistical
analysis. Another possibility for the discrepancy is that we
examined expression in whole blood collected in PAXgene RNA
tubes, which stabilizes RNA on collection, and includes a high
proportion of neutrophil RNA. One possibility is that miR-17 is
very labile, and if it degraded in the 90 minutes or so longer it took
Lindberg et al [30] to purify their miRNA - it could have degraded
preferentially in the healthy control cells because of the different
regulatory environment. Also, it may be that miR-17 is down-
regulated in MS neutrophils cf controls, so that the net miR-17 we
measured was less, even if it was more abundant in MS CD3 cells.
Even if the miRNAs under-expressed in MS were not directly
contributing to the immune cell signature observed in MS whole
blood, the excessive T cell activation signature seen in MS [15–
17]; and other autoimmune diseases [32] suggest agents which can
Figure 2. Gene networks dysregulated in MS are regulated by miR-17 and miR-20a miRNAs. The pathways enriched with genes both
dysregulated in MS-whole blood and modulated in miR-17/20a transformed Jurkat cells were identified using Metacore (Tables S4 and S5). Most
significant pathways are represented in the form of pie-charts where each slice represents 2log10 of the p-value of that pathway as a proportion of
the sum of the 2log10 of the p-values of the over-represented pathways (P,0.05 for miR-17, p,0.001 for miR-20a and mRNA (MS vs. HC)). The p-
values were determined by Metacore Pathway analysis based on the chi squared value for the expected compared to observed number of genes
identified from that pathway in the list of dysregulated genes. (DE differential expression).
doi:10.1371/journal.pone.0012132.g002
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suggests, that the miRNAs identified here as under-expressed in
MS, especially miR-17 and miR-20a, are regulators of genes
involved in T cell activation.
Methods
Ethics Statement
Human Research Ethics Committees from the Sydney West
Area Health Service, The Hunter New England Area Health
Service and the Gold Coast Hospital approved this study. Written
informed consent was given by all participants.
Patients and sample collection
Peripheral blood samples were collected from MS patients and
healthy controls in PAXgene
TM Blood RNA tubes (Qiagen,
Germany). Patients were recruited from Westmead Millennium
Institute, Sydney (NSW), John Hunter Hospital, Newcastle (NSW)
and Griffith University Gold Coast (QLD). Healthy controls, with
no history of any autoimmune disease or any immunomodulatory
therapy, were recruited from Westmead Millenium Institute,
Sydney (NSW) and the John Hunter Hospital, Newcastle, (NSW).
Patient and healthy controls samples were collected between 0900h
and 1300h over the period of one year and collected in PAXgene
tubes (PAXgene
TM Blood RNA kit Qiagen, Hilden, Germany).
Patientshad receivednoimmunomodulatorytherapywithinthelast
3 months. MS diagnosis was according to Poser and McDonald
criteria. The mean age of the MS patients was 54.2 years, and the
controls 40.8 years. The mean age of the PPMS patients was 57.1
years; the mean age of the SPMS patients was 57.2 years and the
mean age of the RRMS patients was 49.9 years (see Table S1).
MiRNA expression analysis
RNA extraction. Patient and healthy control samples were
processed concurrently to prevent batch effects. Frozen PAXgene
blood RNA samples were thawed overnight at room temperature,
centrifuged (4 minutes, 3,000g), and the supernatant discarded.
The pellet was resuspended in 1ml TRIzol reagent (Invitrogen),
briefly vortexed and homogenised. TRIzol RNA extraction was
continued according to manufacturer’s instructions. Briefly, 200ml
chloroform was added, mixed thoroughly, incubated for 2 minutes
at room temperature and centrifuged (15 minutes, 12,000g, 4uC).
The aqueous phase containing the RNA was removed and added
to 500ml isoproanol, incubated for 10 minutes at room
temperature and centrifuged (10 minutes, 12,000g, 4uC). The
supernatant was removed and the RNA pellet washed in 1ml 75%
ethanol and centrifuged (5 minutes, 7,500g, 4uC) (repeated once).
The supernatant was removed and the RNA resuspended in 20ml
water.
The total RNA concentration was determined using RiboGreen
(Ambion, TX) quantitation according to manufacturer’s protocol.
Illumina miRNA SAM methods. MiRNA microarray assay
using Illumina sentrix array matrix (SAM) was performed
according to manufacturer’s instructions (Illumina, CA) using 59
MS patients (24 RRMS, 17 SPMS and 18 PPMS) and 37 healthy
controls. Briefly, 200ng total RNA was polyadenylated, reverse-
transcribed and biotinylated. The cDNA was used in a second
strand synthesis reaction, and universal amplification reaction
involving the incorporation of a fluorescent marker. The labeled
product was hybridised to the SAM and imaged using the Illumina
BeadArray reader.
The microarray data was submitted to the gene expression
omnibus (www.ncbi.nlm.nih.gov/geo/) under access number
GSE21079.
Differential Expression Analysis. Data was quantile
normalised by Illumina’s BeadStudio V3. The differentially
expressed miRNAs between MS and HC were identified using
Significance Analysis of Microarray at a false discovery rate of less
than 1%.
Real time PCR confirmation. Two miRNAs, miR-17 and
miR-20a, were selected for quantitative PCR confirmation, using
endogenous control U49. The sample cohort differs slightly from
the cohort used in the microarray experiment (see table S1) due to
small amount of RNA isolated from some samples, and the
inclusion of extra samples which were not used on the 96 sample
microarray. Final samples numbers were 57 MS (25 RRMS, 14
SPMS and 18 PPMS), and 34 healthy controls.
Reverse transcription of miRNA was performed on 11.35ng
total RNA using the TaqMan miRNA Reverse Transcription Kit
(Applied Biosystems), and pooled miRNA-specific primers. qPCR
was performed using TaqMan miRNA assays (Applied Biosystems,
CA) specific for each miRNA in triplicate for each sample. The
sample was repeated if the standard deviation between triplicates
was greater than 0.33.
The relative expression level was calculated using the compar-
ative Ct method, and an unpaired, one-tailed t-test performed to
test for significant difference between the entire MS cohort, as well
as subtypes compared to the healthy controls.
miRNA-perturbed gene expression analysis
Cell transfection. Jurkat cell cultures were maintained in
suspension at 37uC with 5% CO2 and 90% humidity in RPMI
1640 supplemented with 10% (vol/vol) foetal calf serum and
2 mM L-glutamine. Synthetic miRNA (Sigma) or LNA modified
antimiRs (Integrated DNA Technologies, CA) were delivered by
electroporation (1mg oligonucleotide per 1610
6 cells) using a
Nucleofector device and reagent V according to the
manufacturer’s instructions (Amaxa, Quantum Scientific, QLD),
performed in triplicate. After 24 hours, cells were harvested by
centrifugation and washed in PBS. Total RNA was then extracted
from the cell pellets in TRIzol according to the manufacturer’s
instructions (Invitrogen, CA).
Whole genome gene expression analysis. 500ng total
RNA from each sample was biotinylated and amplified using
Illumina TotalPrep RNA Amplification Kit (Ambion, TX)
according to manufacturer’s instructions. The cRNA yield was
measured at using RiboGreen RNA quantitation kit (Invitrogen,
CA) and 750ng of cRNA sample was hybridized on a human HT-
12 expression beadchip (Illumina, CA) profiling 48,804 transcripts
per sample. The chips were stained with streptavidin and scanned
using an Illumina BeadArray Reader. Three biological replicates
were performed for each transfection experiment.
Differential gene expression analysis. BeadStudio V3 was
used to cubicspline normalise thedata,withQuantilenormalisation
and baseline transformation to median of all samples performed in
GeneSpring GX10. Gene expression profiles from miRNA and
antimiRs electroporated Jurkat cells were generated and compared
with profiles derived from untreated cells, and those electroporated
with non-targeting control oligonucleotides using GeneSpring
(unpaired t-test, p,0.05). Genes down regulated in response to
the introduction of synthetic miRNA or up regulated in response to
the introduction of the miRNA targeting anitmiR were cross-
matched with the respective miRNA target genes predicted by a
range of target algorithms supported by the miRecords target
gene meta site (http://mirecords.umn.edu/miRecords/prediction_
query.php). In order to capture a broad range of potential target
sites, the conditions were set such that each target only need to
satisfy the criteria for two out of a possible 11 different search
MiRNAs in Multiple Sclerosis
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response to specific changes miRNA expression in electroporated
cells were then examined to determine their potential for biological
implications in the context of MS.
Supporting Information
Table S1 Demographics of multiple sclerosis and control
individuals. MS Multiple Sclerosis; RRMS relapsing remitting
MS; SPMS secondary progressive MS; PPMS primary progressive
MS; EDSS Expanded disability status scale
Found at: doi:10.1371/journal.pone.0012132.s001 (0.06 MB
PDF)
Table S2 Genes dysregulated in miR-17 knock-in and knock-
down Jurkat transformants. DE - differential expression; MS -
Multiple Sclerosis; red - up-regulated in MS; black - down-
regulated in MS
Found at: doi:10.1371/journal.pone.0012132.s002 (0.28 MB
PDF)
Table S3 Genes dysregulated in miR-20a knock-in and knock-
down Jurkat transformants. DE - differential expression; MS -
Multiple Sclerosis; red - up-regulated in MS; black - down-
regulated in MS
Found at: doi:10.1371/journal.pone.0012132.s003 (0.37 MB
PDF)
Table S4 Gene networks implicated in Multiple Sclerosis (MS)
pathogenesis from miR-17 knock-in and -down experiments and
from mRNA expression in whole blood.
Found at: doi:10.1371/journal.pone.0012132.s004 (0.07 MB
PDF)
Table S5 Gene networks implicated in Multiple Sclerosis (MS)
pathogenesis from miR-20a knock-in and -down experiments and
from mRNA expression in whole blood.
Found at: doi:10.1371/journal.pone.0012132.s005 (0.04 MB
PDF)
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